CytomX is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies using its proprietary PROBODY platform technology, which conditionally activates masked biologics to reduce toxicity in healthy tissues while preserving anti-tumor activity in the tumor microenvironment. The company's pipeline includes multiple programs across modalities such as antibody-drug conjugates, T-cell engagers, and cytokine therapeutics targeting solid tumors and hematologic malignancies. CytomX generates revenue through upfront payments, research funding, and milestone payments from strategic partnerships with leading biopharmaceutical companies, rather than from commercial product sales.